The deal – financial terms of which were not disclosed – will see the ex-Hospira facility become part of Avara’s six-strong network of manufacturing plants.
Avara stated that it will maintain the current production output and 250-strong workforce employed at the facility.
The Liscate plant will be the second Avara has bought from a major drug maker in two years. Last September it acquired AstraZeneca’s Crestor active pharmaceutical ingredients (API) facility in Avlon, UK, also taking on 210 people employed at the site.
A few months later Canadian authorities banned all non-medically necessary products made at the site, including own brand nausea treatments and the injectable vitamin supplement Calcijex that Hospira produced for AbbVie.
Drugs not covered by the ban – included the injectable monoclonal antibody-based respiratory syncytial virus (RSV) vaccine Synagis (palivizumab) which Hospira made for AbbVie.